Hamilton Catherine L, El Khoury Hala, Hamilton David, Nicklason Frank, Mitrofanis John
Department of Anatomy F13, University of Sydney, 2006, Sydney, Australia.
Geriatric Medicine, Royal Hobart Hospital, Hobart, Australia.
Photobiomodul Photomed Laser Surg. 2019 Oct;37(10):615-622. doi: 10.1089/photob.2019.4663. Epub 2019 Sep 19.
Parkinson's disease is a well-known neurological disorder with distinct motor signs and non-motor symptoms. We report on six patients with Parkinson's disease that used in-house built photobiomodulation (PBM) helmets. We used "buckets" lined with light-emitting diodes (LEDs) of wavelengths across the red to near-infrared range (i.e., 670, 810, and 850 nm; = 5) or an homemade intranasal LED device (660 nm; = 1). Progress was assessed by the patients themselves, their spouse, or their attending medical practitioners. We found that 55% of the initial signs and symptoms of the six patients showed overall improvement, whereas 43% stayed the same and only 2% got worse. We also found that PBM did not target a specific sign or symptom, with both motor and nonmotor ones being affected, depending on the patient. In summary, our early observations are the first to note the impact of PBM on patients' signs and symptoms over an extended period, up to 24 months, and lays the groundwork for further development to clinical trial.
帕金森病是一种众所周知的神经系统疾病，具有明显的运动体征和非运动症状。我们报告了6例使用内部制造的光生物调节（PBM）头盔的帕金森病患者。我们使用了内衬发光二极管（LED）的“桶”，其波长范围从红色到近红外（即670、810和850纳米；n = 5），或一个自制的鼻内LED装置（660纳米；n = 1）。由患者本人、其配偶或主治医生评估进展情况。我们发现，6例患者的初始体征和症状中有55%总体上有所改善，43%保持不变，只有2%恶化。我们还发现，PBM并不针对特定的体征或症状，运动和非运动体征和症状都会受到影响，具体取决于患者。总之，我们的早期观察首次指出了PBM在长达24个月的较长时间内对患者体征和症状的影响，并为进一步发展到临床试验奠定了基础。
